TITLE

Negotiating the RNAi patent thicket

AUTHOR(S)
Schmidt, Charlie
PUB. DATE
March 2007
SOURCE
Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p273
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the investigation of RNA interference (RNAi) patents in the United States. Sirna Therapeutics Inc. collected all the RNAi patents in existence since it started in Boulder, Colorado. Sirna has since sold its business to Merck of Whitehouse Station, New Jersey. The therapeutic potential of RNAi is unknown but it has become invaluable in research.
ACCESSION #
24279325

 

Related Articles

  • Targeted Genetics acquires rights to Huntington's program from Sirna.  // PharmaWatch: Biotechnology;May2008, Vol. 7 Issue 5, p18 

    The article reports that Targeted Genetics Corp. has acquired full exclusive rights to its preclinical Huntington's disease (HD) program from Sirna Therapeutics Inc. In exchange for these rights, Targeted Genetics will pay Sirna an undisclosed royalty on future sales. Sirna has also assigned to...

  • Alnylam, Merck Part Ways; RNAi Stalemate Over.  // Bioworld Week;9/24/2007, Vol. 15 Issue 39, p4 

    The article reports on the move of Alnylam Pharmaceuticals Inc. and Merck & Co. Inc. to part ways 10 month after Merck made known its plan to buy Alnylam's rival in the RNAi space, Sirna Therapeutics Inc. in the U.S. It states that Alnylam has rescinded all grants of its intellectual property...

  • Merck & Co.: Sirna takeover heralds end of alliance.  // PharmaWatch: Biotechnology;Nov2007, Vol. 6 Issue 11, p16 

    The article reports on the end of the research collaboration between Alnylam Pharmaceuticals Inc. and Merck & Co. Inc. Alnylam's decision to withdraw intellectual property rights granted to Merck is attributed to the conflict of interest that followed Merck's takeover of Sirna Therapeutics Inc....

  • THE SOUND OF RNA SILENCING. Minkel, JR // Genomics & Proteomics;Mar2005, Vol. 5 Issue 2, pS5 

    Focuses in the increasing popularity of using RNA interference for the development of novel therapeutics. Efforts of developing the technology to address various medical purposes; Citation of the research conducted by Sirna Therapeutics Inc.; Development of DNA vectors that encode one or more...

  • The Sound of RNA Silencing. Minkel, J.R. // Drug Discovery & Development;Aug2004, Vol. 7 Issue 8, p28 

    Discusses the efforts of pharmaceutical companies to develop novel therapeutics based on the utility of RNA interference. Sirna Therapeutics; Alnylam; Benitec; Cytrx; Genta; Mirus Bio. INSET: But does it make antisense.

  • All dose groups of siRNA show positive change in visual acuity. Charters, Lynda // Ophthalmology Times;5/1/2006, Vol. 31 Issue 9, p64 

    The article reports on the finding that intravitreal injection of a small interfering RNA molecule called the Sirna-027 from Sirna Therapeutics Inc., for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration. the design of Sirna-027 targets vascular...

  • UK PATENTS ON SIRNAS FOR VEGF AND HCV. Tolchin, Elizabeth // Drug Discovery & Development;Aug2005, Vol. 8 Issue 8, p18 

    Reports on the grant of two patents to Sirna Therapeutics Inc. by the Great Britain Patent Office on short interfering RNA (siRNA). Use of the company of siRNA for the treatment of diseases; Coverage of the patents; Advantages of the siRNA; Other patents of the company.

  • After a Bumpy Road, Can RNA Therapeutics Prosper in 2013? Orelli, Brian // BioWorld Insight;1/ 7/2013, Vol. 21 Issue 2, p3 

    The article reports on several perspectives from biopharmaceutical executives on the development of RNAi technology in 2013. It cites the hopes of Sirna Therapeutics Inc.'s chief operations officer (COO) Nassim Usman which has triggered Merck & Co. Inc. to purchase Sirna ten years ago which has...

  • First siRNA Compound Trial in Humans.  // Drug Discovery & Development;Jun2005, Vol. 8 Issue 6, p18 

    The article reports that a group of clinical investigators at Sirna Therapeutics Inc. have presented interim data from an ongoing phase I trial for Sirna-027, a short interfering RNA (siRNA) therapeutic for treatment of Age-Related Macular Degeneration (AMD). Sirna-027 targets vascular...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics